Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2189 plus HRS-5041 in Metastatic Prostate Cancer
NCT06738745Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of hrs-2189, HRS-5041 in Metastatic Prostate Cancer (mPC), sponsored by Fudan University. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
hrs-2189HRS-5041
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT06738745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738745.